Nivolumab plus ipilimumab for the first-line treatment of metastatic NSCLC.

In the last decade, immune checkpoint inhibitors have revolutionized the treatment of several malignancies including non-small cell lung cancer (NSCLC). The inhibition of cytotoxic T-lymphocyte-ass...